BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
BNT162b2 mRNA vaccine
Booster effect
COVID-19
Reactogenicity
SARS-CoV-2
T-cell responses
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
17 12 2021
17 12 2021
Historique:
received:
29
05
2021
revised:
15
10
2021
accepted:
27
10
2021
pubmed:
23
11
2021
medline:
24
12
2021
entrez:
22
11
2021
Statut:
ppublish
Résumé
We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naïve individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naïve HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines. Study Registration. The study was registered on clinicaltrials.gov, NCT04402827.
Identifiants
pubmed: 34802792
pii: S0264-410X(21)01417-1
doi: 10.1016/j.vaccine.2021.10.074
pmc: PMC8580836
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
BNT162 Vaccine
N38TVC63NU
Banques de données
ClinicalTrials.gov
['NCT04402827']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
7367-7374Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Front Immunol. 2017 Aug 14;8:943
pubmed: 28855902
J Infect Dis. 2021 Jul 15;224(2):241-245
pubmed: 33961690
Postgrad Med. 2021 Jan;133(1):10-19
pubmed: 33131380
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
NPJ Vaccines. 2019 Sep 24;4:39
pubmed: 31583123
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33058753
Sci Transl Med. 2022 Feb 09;14(631):eabi8961
pubmed: 34874183
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell Rep. 2021 Aug 24;36(8):109570
pubmed: 34390647